Cytokines News and Research

Latest Cytokines News and Research

SARS-CoV-2 Delta spike increases viral virulence and inflammatory cytokine production

In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.

29 Nov 2021

SARS-CoV-2 can directly invade human kidney cells, research shows

Up to 25% of patients' COVID-19 cases involve acute kidney injury—the kidneys' equivalent of a heart attack.

29 Nov 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Maternal-fetal interface yields intriguing clues to how it battles SARS-CoV-2

Scientists have hypothesized that the number of immune cells and the amount of cytokines produced in response to SARS-CoV-2 infection in pregnant women change in accordance with the timing of maternal infection in pregnancy. This study is available on the bioRxiv* preprint server.

24 Nov 2021

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

A new study, published on the bioRxiv* preprint server, hypothesized that ACE-2 expression and ADAM17 activity in the placenta is affected by the timing of SARS-CoV-2 infection of the mother.

24 Nov 2021

The antimicrobial properties of the lungfish cocoon

Researchers investigate if the immune system of lungfish plays a role in estivation.

24 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

Study shows SARS-CoV-2 can infect and replicate in human iPSC-derived neurons

In a study recently published on the bioRxiv preprint server, researchers attempted to further increase the scope of previous studies in examining SARS-CoV-2 infection of human CNS resident cells.

22 Nov 2021

Interferon beta versus the SARS-CoV-2 Delta variant

In a study recently published on the bioRxiv* preprint server, researchers investigated the difference in replication efficiency or IFN sensitivity of the four VOCs.

22 Nov 2021

Human lung airway-on-a-chip faithfully recapitulates cystic fibrosis pathology

The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices.

21 Nov 2021

Functions of glycosylation in SARS-CoV-2 proteins and human receptor ACE2

In a review published in Signal Transduction and Targeted Therapy, researchers from Sichuan University have reviewed the available literature.

19 Nov 2021

Severe COVID-19 patients have significantly higher NK and T cell frequency

A new study published in the open-access journal Cells aimed to clarify the role of NK and T cell subsets in SARS-CoV-2 infection in hospitalized COVID-19 patients to unravel their potential association with disease severity.

18 Nov 2021

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

18 Nov 2021